RECANATI LEON purchased $292K of EVGN
RECANATI LEON purchased 460,000 shares of Evogene Ltd. (EVGN) at $0.64 ($0.29M total) on 2026-08-11.
How this was made
The 30-second read
Why it matters
The newest fact is the director’s open-market purchase details (shares, price, total value, and post-transaction holdings).
Market read
Traders may treat the filing as a mild sentiment input, but it does not introduce new fundamentals in the provided text.
What to watch
The article provides no context on prior insider activity, motivations, or whether the purchase was funded by liquidity events, so traders should avoid over-weighting it.
Background
The article is a SEC Form 4 insider transaction disclosure for Evogene Ltd.
Ticker impact
Evogene director Leon Recanati filed a Form 4 open-market purchase of 460,000 shares at $0.6350 on 2026-08-11.
Likely limited near-term impact; any effect is sentiment-driven and typically fades unless followed by additional disclosures.
The filing is a primary-source Form 4 and the transaction size is notable, but there is no accompanying guidance, deal, or regulatory/clinical update in the text.
Market effects
No sector-wide implications are stated; this is company-specific insider activity.
None indicated.
None indicated.
Counterpoint
Insider open-market buys can be routine or planned; without a 10b5-1 plan and without follow-on news, the signal may be weak.
Key entities
- issuerEvogene Ltd.
Subject of the Form 4 insider transaction disclosure (EVGN).
- insiderRECANATI LEON
Director who reported the open-market purchase of 460,000 shares.